Business Context and Reporting Period
This Form 8-K Current Report was filed by Shuttle Pharmaceuticals Holdings, Inc. on March 7, 2023. The Company is a Delaware corporation with its principal executive offices in Rockville, Maryland, and its common stock trades on The Nasdaq Stock Market under the symbol "SHPH". The report details a material definitive agreement entered into by the Company's wholly-owned subsidiary, Shuttle Pharmaceuticals Inc.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed relates to the new service agreement:
- Agreement Cost: Total estimated cost of $619,294 for formulation development and clinical batch manufacture services.
Material Changes
The primary material event reported is the entry into a Proposal for Service Agreement with University of Iowa Pharmaceuticals (UI Pharmaceuticals) on March 7, 2023. Key terms include:
- Scope: Formulation development and analytical laboratory services for drug capsules of Ropidoxuridine.
- Term: March 6, 2023, to June 4, 2023.
- Counterparty: University of Iowa Pharmaceuticals.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosures associated with the agreement. The Company notes that certain portions of the attached Service Agreement exhibit have been redacted due to confidential and proprietary nature, though the Company deems the redacted information not material to understanding the underlying rights and obligations.
Investor Verification Checklist
- Verify the status of the Ropidoxuridine drug development program and the necessity of the clinical batch manufacture.
- Confirm the Company's current cash position to ensure it can fund the $619,294 estimated cost without immediate dilution or debt.
- Review the full text of Exhibit 10.1 (Service Agreement) for any termination clauses or performance milestones not detailed in the summary.
- Monitor subsequent filings for any updates on the agreement's execution or changes in the estimated cost.